Nektar Therapeutics (NKTR) PT Lowered to $41 at BMO Capital
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $73.02 -3.82%
Rating Summary:
20 Buy, 7 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
20 Buy, 7 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BMO Capital analyst George Farmer lowered the price target on Nektar Therapeutics (NASDAQ: NKTR) to $41.00 (from $75.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
- Nektar Therapeutics Announces Second Quarter 2026 Financial Results
- GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
